NASDAQ: IONS

Ionis Pharmaceuticals (IONS) Stock Analysis & Forecast

Nov 13 close

$29.06+1.75 (+6.4%)

Gekko Brief

AI summaryNov 9 close

Ionis shares fell sharply this week after third-quarter results. The company reported sales up 54.78% to $243 million, beating estimates, and narrowed its adjusted loss per share to $(0.40), ahead of consensus. Despite these beats, Ionis lowered its 2026 TRYNGOLZA revenue guidance to approximately $50 million, down from a prior target of $100 million to $110 million, citing slower-than-expected uptake and competitive pressure in severe hypertriglyceridemia. DAWNZERA's third-quarter product sales rose 40% to $37 million. The company also pushed back its target for sustained positive cash flow by a year, and at least one law firm has announced an investigation notice tied to the guidance cut.

IONS closed at $31.00, down 21.4% on the day and now at a 52-week low, with the 52-week range spanning $27.75 to $86.74. The stock trades below both its 50-day average of $46.20 and its 200-day average of $65.58, with the shorter average itself below the longer one, reflecting a one-month decline of 31.5% and a six-month decline of 58.9%. The GekkoIndex reads 78.5, placing the stock in the Buying zone. Price sits 48.5% below the Gekko Fair Value of $60.15.

No confirmed earnings date appears on the calendar following the 29 July 2026 report, where Ionis beat EPS estimates and the stock moved -3.7% on the news. Over the last 30 days, 2 unusual options signals were recorded, with call premium of $333,630 against put premium of $250,635. One trailblazer holder is noted. Seasonality over the next 20 trading days has averaged -2.3% across 5 years, rising in 2 of them, a pattern worth noting given current volatility, with a typical 20-day move of 6.2%.

Written by AI from the Nov 9, 2026 close and checked automatically against the figures on this page.

Ionis Pharmaceuticals price vs fair value

$52.36$29.06Nov ’25May ’26Nov ’26
Close $29.06200-day averageGekko Fair Value $52.36

Ionis Pharmaceuticals quick facts

Market cap
$4.84B
P/E ratio
—
Forward P/E
90.9
EPS, TTM
−$3.35
Revenue, TTM
$960.1M
Profit margin
-56.9%
Dividend yield
—
Beta
0.40
Volume
5.93M avg 4.57M
1-year return
−60.0%
Typical daily move
±8.9%
Typical 20-day move
±6.2%
50-day average
$43.66
200-day average
$64.50
Next earnings
Feb 24
Shares outstanding
166.5M
52-week range
$27.25$86.74

Ionis Pharmaceuticals swing-trade checklist

Ionis Pharmaceuticals scores 4 supportive, 0 mixed and 2 headwinds across the 6 checklist items with data.

Six things swing traders check before a 20-day hold, read from the latest data.

4 supportive0 mixed2 headwinds

  • Trendheadwind

    Below 50 and 200-day

    Close $29.06 is below the 50-day ($43.66) and 200-day ($64.50) averages, and the 50-day is below the 200-day.

    See the chart
  • GekkoIndexsupportive

    76.4, Buying

    Reading 76.4 is in the Buying zone.

    See the GekkoIndex
  • Fair valuesupportive

    44.5% below

    Price is 44.5% below Gekko Fair Value (more than 5% below).

    See fair value
  • Smart moneysupportive

    Leans bullish

    Last 90 days: 1 open-market insider purchase. Last 30 days: 2 unusual options signals.

    See smart money
  • Earnings risksupportive

    Reports in 101 days

    Next report Feb 24, 2027, 101 days away — outside a typical 20-trading-day hold.

    See earnings
  • Seasonalityheadwind

    −2.3% on average

    From this point in the calendar, the next 20 trading days averaged −2.3% over 5 years, rising in 1 of them.

    See seasonality

A description of current data, not a recommendation. How this page works

Ionis Pharmaceuticals stock chart and price history

Ionis Pharmaceuticals closed at $29.06 on Nov 13, 2026, −60.0% over the past year, inside a 52-week range of $27.25 to $86.74.

Close50-day average200-day averageVolume
Ionis Pharmaceuticals share price, past year, with 50-day and 200-day moving averages and volume$40$60$80DecJan 2026FebMarAprMayJunJulAugSepOctNov29.06

Use the left and right arrow keys to read daily values.

Performance Breakdown

1 month
−34.1%
3 months
−50.4%
6 months
−60.9%
1 year
−60.0%
The full IONS chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open IONS in Gekko

Follow Ionis Pharmaceuticals through every session

Put IONS on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.

Track IONS in GekkoFree for 7 days. No credit card required.

About Ionis Pharmaceuticals

Ionis Pharmaceuticals works on medicines built around RNA-targeting technology, focused on treating rare and genetic conditions. Its marketed products include a therapy for spinal muscular atrophy, an injectable for a nerve condition linked to hereditary transthyretin-mediated amyloidosis, and a treatment for two rare lipid disorders. The company has become associated with this RNA-based approach to drug design.

Beyond its approved medicines, Ionis runs a pipeline of candidates in late-stage trials, covering conditions such as TTR amyloidosis, severe high triglycerides, hereditary angioedema, ALS, cardiovascular disease tied to elevated lipoprotein(a), and a genetic form of ALS treated through inhibiting a specific protein's production. It also researches treatments in metabolic, infectious, renal, ophthalmic and oncology areas. Much of its work is carried out through partnerships, including a strategic collaboration with Biogen, along with licensing and collaboration agreements with AstraZeneca, Bayer, GlaxoSmithKline, Novartis, Roche, Janssen Biotech and Flamingo Therapeutics.

Ionis Pharmaceuticals was founded in 1989 and is headquartered in Carlsbad, California. Its shares are listed on the NASDAQ under the ticker IONS.

Listed
NASDAQ
Sector
Health technology
Industry
Pharmaceuticals: major
Website
ionis.com

Ionis Pharmaceuticals GekkoIndex: the smart money zone

Ionis Pharmaceuticals’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 76.4, in the Buying zone, up 6.9 points over five sessions.

010076.4Buying

Up 6.9 points over five sessions, from the Accumulation zone.

Reading for Nov 13, 2026

What followed past readings in each zone

ZoneReadings5 days10 days20 days50 days
Buying (current zone)54+0.3%+0.1%+1.6%−3.3%
Accumulation259−0.7%−0.5%−1.2%−3.2%
Neutral346+0.6%+0.8%+1.1%+5.5%
Distribution38−0.5%−1.0%+1.9%+18.0%
Selling5Too few readings yet

Average IONS share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Buying readings averaged +2.9% over 20 days. Past behaviour doesn’t guarantee future results.

Buying zone: Smart money likely accumulating heavily. About the five zones →

See every daily GekkoIndex reading plotted over the IONS price, zone by zone.Track IONS in Gekko

Is Ionis Pharmaceuticals stock overvalued? Gekko Fair Value

Ionis Pharmaceuticals trades 44.5% below Gekko Fair Value of $52.36, so the shares are undervalued on Gekko’s estimate.

Gekko’s own estimate of what Ionis Pharmaceuticals shares are worth, recalculated every trading day.

$52.36

Gekko Fair Value, Nov 14, 2026

44.5% Undervalued

At the end of Aug 2026 the price was 23.7% below the estimate.

Gekko Fair ValueShare price, month end
$52$29Aug 2026SepOctNov 2026

How Gekko Fair Value works →

Gekko Fair Value on every chart, with the gap to price updating daily.Open IONS in Gekko

Ionis Pharmaceuticals insider and Congress trading

Insiders filed 1 open-market purchase in Ionis Pharmaceuticals worth $148K, and no Congress trades were disclosed, in the last 90 days.

Plus buybacks, unusual options and fund positions, each dated to when it became public.

Insider buying last 90 days

$148Kin 1 open-market purchase

FiledInsiderTypeSharesValue
Nov 13Hayden Michael R
director
Purchase5,000$148K

From Form 4 filings, dated to when each was filed.

Congress trades last 90 days

No trades in IONS were disclosed by members of Congress in the last 90 days.

From congressional disclosures, which report amounts as ranges.

Congress disclosures for IONS, plotted on the chart in Gekko.Open IONS in Gekko

Buybacks

Ionis Pharmaceuticals has been buying back its own shares.

Bought back, year ended Dec 31, 2020
$90.55M
As a share of market cap
1.87%

From company filings.

Unusual options activity last 30 days

2signals, 57% of the flagged premium in calls.

Latest: Bearish flow on Oct 30, $251K in unusual premium.

Hedge funds and billionaires quarter ended Sep 30

0of the funds Gekko tracks hold IONS.

0added0opened0trimmed1sold out
Every signal with its contract, strike and premium, and which funds are on each side.Unlock in Gekko

Ionis Pharmaceuticals earnings: next date and track record

Ionis Pharmaceuticals reports on Feb 24, 2027 (101 days away), and beat the EPS estimate in 7 of its last 8 reports.

7 of 8reports beat the EPS estimate
±6.9%average move across the report
5 of 8reports followed by a gain

Share-price move across each report

+2.3%Feb ’25+6.4%Apr ’25+3.6%Jul ’25+0.8%Oct ’25−5.7%Feb ’26+4.2%Apr ’26−3.7%Jul ’26−28.5%Nov ’26

Last earnings call, Nov 9, 2026 AI summary

What they said
Ionis reported Q3 2026 results showing commercial portfolio expansion with four products: TRYNGOLZA (FCS and sHTG), DAWNZERA (HAE), and ZANVASTRO (neurology). Two Phase III trials missed endpoints, but HIBSAGO received U.S./Japan approval for hepatitis B, and positive Phase III data emerged for Sefaxersen and ulefnersen. Full year 2026 total revenue, operating loss, and cash guidance remain on track despite TRYNGOLZA launch challenges.
Guidance
TRYNGOLZA 2026 revenue guidance lowered to approximately $50 million due to slower-than-expected launch ramp in sHTG. DAWNZERA momentum supports its 2026 product sales guidance. Overall 2026 total revenue, operating loss, and cash guidance maintained.
ReportedEPSSurpriseRevenueSurpriseMove
Nov 9, 2026−$0.66
est −$1.23
+46.3%$243.0M
est $178.2M
+36.4%−28.5%
Jul 29, 2026−$0.70
est −$1.09
+35.8%$268.0M
est $189.1M
+41.7%−3.7%
Apr 29, 2026−$0.30
est −$0.77
+61.0%$246.0M
est $195.6M
+25.8%+4.2%
Feb 25, 2026−$1.41
est −$1.24
−14.0%$203.0M
est $156.1M
+30.1%−5.7%
Oct 29, 2025−$0.61
est −$1.15
+47.0%$156.7M
est $153.6M
+2.1%+0.8%
Jul 30, 2025$0.86
est $0.27
+218.5%$452.0M
est $131.7M
+243.1%+3.6%
Apr 30, 2025−$0.93
est −$1.13
+17.7%$131.6M
est $150.6M
−12.6%+6.4%
Feb 19, 2025−$0.43
est −$0.84
+49.0%$226.6M
est $131.1M
+72.8%+2.3%

“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.

Ionis Pharmaceuticals stock forecast and analyst price targets

Analysts’ average 12-month price target for Ionis Pharmaceuticals is $69.13, +137.9% from the last close, from 19 firms rating the stock in the last 90 days.

$69.13consensus 12-month target, +137.9% from the last close
Low $41High $100
Buy18
Hold1
Sell0

Each firm’s latest rating in the last 90 days: 19 firms.

Latest analyst actions

DateFirmRatingTargetvs price
Nov 10Wells FargoBuy, reiterated$80+175.3%
Nov 10TD CowenBuy, maintained$53+82.4%
Nov 10OppenheimerBuy, reiterated$70+140.9%
Nov 10H.C. WainwrightBuy, maintained$70+140.9%
Nov 10Goldman SachsHold, reiterated$41+41.1%
+1.6%average 20-day move after past Buying readings
−2.3%average move over the next 20 trading days in the last 5 years
±8.9%typical daily move, from the 14-day average range

Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.

Ionis Pharmaceuticals seasonality: the next 20 trading days

Over the next 20 trading days from Nov 14, Ionis Pharmaceuticals averaged −2.3% across the last 5 years, rising in 1 of them.

Next 20 trading days, by year

−7.7%2021−13.4%20220.0%2023−1.7%2024+11.5%2025

Average move and hit rate

WindowAverageYears higher
Next 5 trading days−2.1%1 of 5
Next 10 trading days−4.2%2 of 5
Next 15 trading days−1.5%2 of 5
Next 20 trading days−2.3%1 of 5
Next 30 trading days−2.8%2 of 5

For scale, IONS’s typical 20-trading-day move in either direction is about 6.2%.

Ionis Pharmaceuticals market cap and key statistics

Ionis Pharmaceuticals’s market cap is $4.84B and revenue of $960.1M over the last twelve months.

Valuation

Market cap
$4.84B
Forward P/E
90.9
EPS, TTM
−$3.35
Gekko Fair Value
$52.36

Trading

Volume
5.93M
Avg volume, 20 days
4.57M
52-week high
$86.74
52-week low
$27.25
Shares outstanding
166.5M

Financials

Revenue, TTM
$960.1M
Profit margin
-56.9%
Return on equity
-108.1%
Quarterly earnings growth, YoY
−43.7%

Risk and income

Beta
0.40
Typical daily move
±8.9%
Typical 20-day move
±6.2%

Ionis Pharmaceuticals peers

Ionis Pharmaceuticals’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.

StockTodayGekkoIndex zonevs Fair Value
LLYEli Lilly+1.0%Neutral24.0% above
JNJJohnson & Johnson+0.3%Neutral4.4% above
ABBVAbbVie−0.5%Neutral23.7% above
MRKMerck+0.3%Neutral8.2% below
AZNAstraZeneca−0.2%Neutral34.6% below
PFEPfizer−0.1%Accumulation8.9% below

A peer links to its own page where one exists.

In the Buying zone today

Reporting earnings this week

Popular on Gekko

More stocks in Pharmaceuticals: major

Ionis Pharmaceuticals stock FAQ

What is Ionis Pharmaceuticals’s market cap?

Ionis Pharmaceuticals’s market cap is $4.84B at the Nov 13, 2026 close of $29.06, with 166.5M shares outstanding.

What is the Ionis Pharmaceuticals stock forecast?

The consensus analyst 12-month price target for Ionis Pharmaceuticals is $69.13, +137.9% from the last close. Of the 19 firms that rated the stock in the last 90 days, 18 rate it a buy, 1 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.

Is Ionis Pharmaceuticals stock overvalued or undervalued?

On Gekko’s estimate Ionis Pharmaceuticals is undervalued: the Nov 13, 2026 close of $29.06 is 44.5% below Gekko Fair Value of $52.36. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.

When does Ionis Pharmaceuticals report earnings next?

Ionis Pharmaceuticals is expected to report on Feb 24, 2027 (101 days away). Analysts expect earnings of −$1.35 per share on revenue of $178.9M. Ionis Pharmaceuticals beat the earnings estimate in 7 of its last 8 reports, moving 6.9% on average across the report.

What is Ionis Pharmaceuticals’s 52-week high and low?

Ionis Pharmaceuticals’s 52-week high is $86.74 and its 52-week low is $27.25; it closed at $29.06 on Nov 13, 2026, −60.0% over the past year.

Is Ionis Pharmaceuticals stock a buy right now?

Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 4 of the 6 items with data read as supportive (gekkoindex, fair value, smart money and earnings risk) and 2 as headwinds (trend and seasonality). The checklist is a description of current data, not a recommendation.

Is there unusual options activity in Ionis Pharmaceuticals?

Gekko flagged 2 unusual options signals in Ionis Pharmaceuticals over the last 30 days, with $334K of flagged premium in calls and $251K in puts. The latest, bearish flow, was on Oct 30, 2026 with $251K in unusual premium. The signal-by-signal table is in Gekko.

How this page works

During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →

See Ionis Pharmaceuticals the way Gekko members do

Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.

Join 1,475 other traders using Gekko

Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.